Indole Metabolites as Modulators of Human Cholinesterases: A Kinetic and Molecular Docking Study with Comparison to Alzheimer’s Drugs
DOI:
https://doi.org/10.58600/eurjther3107Keywords:
Alzheimer’s disease, Cholinesterase inhibition, Enzyme kinetics, Indole metabolites, Molecular dockingAbstract
Objective: Alzheimer’s disease (AD) is characterised by the gradual decline of cognitive function and impaired cholinergic neurotransmission due to reduced brain acetylcholine levels. AChE and BChE regulate acetylcholine degradation and are important targets in AD. This research investigated the inhibitory effects of indole-3-propionic acid (IPA) and indole-3-butyric acid (IBA) on human cholinesterases, using enzyme kinetics and molecular docking.
Methods: We assessed the inhibitory effects of purified human BChE and commercially sourced erythrocyte-derived AChE using a modified Ellman spectrophotometric assay in a 96-well microplate. Kinetic parameters (Km, Vmax, and Ki) were determined by nonlinear regression and the Michaelis–Menten model, with Lineweaver–Burk plots used to analyse inhibition patterns. IC50 values were calculated by nonlinear regression analysis. Molecular docking simulations were performed to predict the binding positions of the indole derivatives and the reference Alzheimer’s drugs donepezil and tacrine analogue in the active sites of AChE and BChE.
Results: According to docking simulations, both indole derivatives bind to the catalytic gorge of cholinesterases, but with lower predicted affinity than reference inhibitors. Enzyme inhibition assays showed that IBA exhibited weak inhibitory activity against both enzymes, with IC50 values of 15.61 mM for BChE and 54.28 mM for AChE. IPA exhibited stronger inhibition, particularly against BChE, with an IC50 of 2056 µM. Kinetic analysis indicated that IPA displays mixed-type inhibition of BChE (Km = 170.1 µM, Ki = 1774 µM), while its inhibition of AChE is competitive (IC50 = 3773 µM, Km = 268.5 µM, Ki = 6727 µM).
Conclusion: These findings suggest that short-chain indole metabolites can interact with cholinesterases, but are not potent inhibitors. Compared to IBA, IPA showed higher activity and distinct inhibition profiles for BChE and AChE. The development of new indole-based cholinesterase inhibitors may prove to be potent modulators of cholinergic enzymes.
References
[1] Sharma P, Srivastava P, Seth A, Tripathi PN, Banerjee AG, Shrivastava SK (2019) Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies. Prog Neurobiol 174:53-89. https://doi.org/10.1016/j.pneurobio.2019.01.002
[2] Kuzu B, Alagoz MA, Demir Y, Gulcin I, Burmaoglu S, Algul O (2025) Structure-based inhibition of acetylcholinesterase and butyrylcholinesterase with 2-Aryl-6-carboxamide benzoxazole derivatives: synthesis, enzymatic assay, and in silico studies. Mol Divers 29(2):671-693. https://doi.org/10.1007/s11030-024-10826-5
[3] Giacobini E (2003) Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res 28(3-4):515-522. https://doi.org/10.1023/a:1022834522495
[4] Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Bazwinsky I, Zerr I, Jelic V, Hoffermann B, Peters O, Gertz HJ, Frölich L, Hausner L, Siemers E, DeKosky S, Winblad B (2014) Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med 275(3):251-283. https://doi.org/10.1111/joim.12191
[5] Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F (2012) New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 73(4):504-517. https://doi.org/10.1111/j.1365-2125.2011.04151.x
[6] Ciriello R, Magro SL, Guerrieri A (2018) Assay of serum cholinesterase activity by an amperometric biosensor based on a co-crosslinked choline oxidase/overoxidized polypyrrole bilayer. Analyst 143(4):920-929. https://doi.org/10.1039/c7an01815k
[7] Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Raecke KC, Gottfries CG (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain 141(7):1917-1933. https://doi.org/10.1093/brain/awy132
[8] Li Y, Hai S, Zhou Y, Dong BR (2015) Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst Rev 2015(3):CD009444. https://doi.org/10.1002/14651858.CD009444.pub3
[9] Zhang LS, Davies SS (2016) Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med 8(1):46. https://doi.org/10.1186/s13073-016-0296-x
[10] Gao K, Mu CL, Farzi A, Zhu WY (2020) Tryptophan metabolism: a link between the gut microbiota and brain. Adv Nutr 11(3):709-723. https://doi.org/10.1093/advances/nmz127
[11] Pavlova T, Vidova V, Bienertova-Vasku J, Janku P, Almasi M, Klanova J, Spacil Z (2017) Urinary intermediates of tryptophan as indicators of the gut microbial metabolism. Anal Chim Acta 987:72-80. https://doi.org/10.1016/j.aca.2017.08.023
[12] Zhang B, Jiang M, Zhao J, Song Y, Du W, Shi J (2022) The mechanism underlying the influence of indole-3-propionic acid: a relevance to metabolic disorders. Front Endocrinol (Lausanne) 13:841703. https://doi.org/10.3389/fendo.2022.841703
[13] Jiang H, Chen C, Gao J (2022) Extensive summary of the important roles of indole propionic acid, a gut microbial metabolite in host health and disease. Nutrients 15(1):151. https://doi.org/10.3390/nu15010151
[14] Negatu DA, Gengenbacher M, Dartois V, Dick T (2020) Indole propionic acid, an unusual antibiotic produced by the gut microbiota, with anti-inflammatory and antioxidant properties. Front Microbiol 11:575586. https://doi.org/10.3389/fmicb.2020.575586
[15] Pappolla MA, Perry G, Fang X, Zagorski M, Sambamurti K, Poeggeler B (2021) Indoles as essential mediators in the gut-brain axis. Their role in Alzheimer's disease. Neurobiol Dis 156:105403. https://doi.org/10.1016/j.nbd.2021.105403
[16] Chadha N, Silakari O (2017) Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view. Eur J Med Chem 134:159-184. https://doi.org/10.1016/j.ejmech.2017.04.003
[17] Sonmez G, Karatas BE, Bodur E (2025) From crude extracts to purity: a comparative study of butyrylcholinesterase purification. Protein J 44(2):259-267. https://doi.org/10.1007/s10930-024-10214-z
[18] Lu C, Wu C, Ghoreishi D, Chen W, Wang L, Damm W, Ross GA, Dahlgren MK, Russell E, Von Bargen CD, Abel R, Friesner RA, Harder ED (2021) OPLS4: Improving force field accuracy on challenging regimes of chemical space. J Chem Theory Comput 17(7):4291-4300. https://doi.org/10.1021/acs.jctc.1c00302
[19] Dileep K, Ihara K, Mishima-Tsumagari C, Kukimoto-Niino M, Yonemochi M, Hanada K, Shirouzu M (2022) Crystal structure of human acetylcholinesterase in complex with tacrine: implications for drug discovery. Int J Biol Macromol 210:172-181. https://doi.org/10.1016/j.ijbiomac.2022.04.184
[20] Chalupova K, Korabecny J, Bartolini M, Monti B, Lamba D, Caliandro R, Pesaresi A, Rivelli M, Upadhyay AK, Mezeiova E, Kučera T, Soukup O, Špirková K, Hepnarová K, Gasperi V, Catanzaro G, Di Giacomo V, Lanciotti A, De Franco F, Angelucci S, Spinozzi S, Vincenzi M, Mazzoni C, Cacciatore I, Fornasari E, Di Stefano A (2019) Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease. Eur J Med Chem 168:491-514. https://doi.org/10.1016/j.ejmech.2019.02.043
[21] Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT, Miller JL, Li X, Sandor M, Day T, Weaver B, Karlak B, Kartner T (2006) Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein− ligand complexes. J Med Chem 49(21):6177-6196. https://doi.org/10.1021/jm051256y
[22] George PM, Abernethy MH (1983) Improved Ellman procedure for erythrocyte cholinesterase. Clin Chem 29(2):365-368. https://doi.org/10.1093/clinchem/29.2.365
[23] Rosenberry TL, Brazzolotto X, Macdonald IR, Wandhammer M, Trovaslet-Leroy M, Darvesh S, Nachon F (2017) Comparison of the binding of reversible inhibitors to human butyrylcholinesterase and acetylcholinesterase: A crystallographic, kinetic and calorimetric study. Molecules 22(12):2098. https://doi.org/10.3390/molecules22122098
[24] Taylor P, Radic Z (1994) The cholinesterases: from genes to proteins. Annu Rev Pharmacol Toxicol 34:281-320. https://doi.org/10.1146/annurev.pa.34.040194.001433
[25] Lane RM, Potkin SG, Enz A (2006) Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J Neuropsychopharmacol 9(1):101-124. https://doi.org/10.1017/S146114570500582X
[26] Orhan I, Kartal M, Tosun F, Şener B (2007) Screening of various phenolic acids and flavonoid derivatives for their anticholinesterase potential. Z Naturforsch C J Biosci 62(11-12):829-832. https://doi.org/10.1515/znc-2007-11-1207
[27] Agus A, Planchais J, Sokol H (2018) Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 23(6):716-724. https://doi.org/10.1016/j.chom.2018.05.003
[28] Chyan YJ, Poeggeler B, Omar RA, Chain DG, Frangione B, Ghiso J, Sambamurti K, Pappolla MA (1999) Potent neuroprotective properties against the Alzheimer β-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol Chem 274(31):21937-21942. https://doi.org/10.1074/jbc.274.31.21937
[29] Roager H, Licht T (2018) Microbial tryptophan catabolites in health and disease. Nat Commun 9(1):3294. https://doi.org/10.1038/s41467-018-05470-4
[30] Gutiérrez-Vázquez C, Quintana F (2018) Regulation of the immune response by the aryl hydrocarbon receptor. Immunity 48(1):19-33. https://doi.org/10.1016/j.immuni.2017.12.012
[31] Grishanova A, Perepechaeva M (2022) Aryl hydrocarbon receptor in oxidative stress as a double agent and its biological and therapeutic significance. Int J Mol Sci 23(12):6719. https://doi.org/10.3390/ijms23126719
[32] Peesh P, Blasco-Conesa M, El Hamamy A, Khan R, Guzman G, Honarpisheh P, McCullough LD, Savarraj JP (2025) Benefits of equilibrium between microbiota- and host-derived ligands of the aryl hydrocarbon receptor after stroke in aged male mice. Nat Commun 16(1):112. https://doi.org/10.1038/s41467-025-57014-2
[33] Soreq H, Seidman S (2001) Acetylcholinesterase--new roles for an old actor. Nat Rev Neurosci 2(4):294-302. https://doi.org/10.1038/35067589
[34] Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I (1991) Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 253(5022):872-879. https://doi.org/10.1126/science.1678899
[35] Hao Z, Ji R, Su Y, Wang H, Yang W, Zhang S, Hao P, Zhang L (2025) Indole-3-propionic acid attenuates neuroinflammation and cognitive deficits by inhibiting the RAGE-JAK2-STAT3 signaling pathway. J Agric Food Chem 73(12):5208-5222. https://doi.org/10.1021/acs.jafc.4c09890
[36] Massoulié J, Pezzementi L, Bon S, Krejci E, Vallette FM (1993) Molecular and cellular biology of cholinesterases. Prog Neurobiol 41(1):31-91. https://doi.org/10.1016/0301-0082(93)90040-8
[37] Bodur E, Cokugras AN (2005) The effects of indole-3-acetic acid on human and horse serum butyrylcholinesterase. Chem Biol Interact 157-158:375-378. https://doi.org/10.1016/j.cbi.2005.10.052
[38] Greig NH, Utsuki T, Yu QS, Zhu X, Holloway HW, Perry T, Sambamurti K, Lahiri DK (2001) A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 17(3):159-165. https://doi.org/10.1185/030079901750406696
[39] Hwang IK, Yoo KY, Li H, Park OK, Lee CH, Choi JH, Kang IJ, Shin HC, Won MH (2009) Indole‐3‐propionic acid attenuates neuronal damage and oxidative stress in the ischemic hippocampus. J Neurosci Res 87(9):2126-2137. https://doi.org/10.1002/jnr.22037
[40] Chen Z, Zhong C (2014) Oxidative stress in Alzheimer’s disease. Neurosci Bull 30(2):271-281. https://doi.org/10.1007/s12264-013-1430-3
Downloads
Published
How to Cite
License
Copyright (c) 2026 Müslüm Gök, Çiğdem Çiçek, Suat Sarı, Gamze Sönmez, Ebru Bodur
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
